Tumor Exosome Liquid Biopsy Strategy To Diagnose Pancreatic Cancer

Study Overview

Tumor Exosome Liquid Biopsy Strategy to Diagnose Pancreatic Cancer

This is an observational study of patients diagnosed with pancreatic cancer by pathology, with a control group of patients with pathology suggestive of benign pancreatic lesions and normal subjects, and the diagnostic ability of exosomes to identify patients with pancreatic cancer was assessed through the detection of exosomes in the peripheral blood.

N/A

Pancreatic

OTHER:

IIT-2023-0118

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2023-10-23	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2023-10-25
First Submitted that Met QC Criteria 2023-10-25	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2023-10-31
First Posted (ACTUAL) 2023-10-31	Results First Posted N/A	Last Verified 2023-10

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
: pancreatic patients Cases will be the patients with newly-diagnosed pancreatic.	OTHER:
: The controls Controls will be selected from patients with pancreatitis from the same hospital as the case, matched by gender, race and age (1:1).	OTHER:

Participant Group/Arm

Intervention/Treatment

: pancreatic patients

Cases will be the patients with newly-diagnosed pancreatic.

OTHER:

: The controls

Controls will be selected from patients with pancreatitis from the same hospital as the case, matched by gender, race and age (1:1).

OTHER:

Primary Outcome Measures	Measure Description	Time Frame
Characterization of proteins in tumor exosomes from patients with pancreatic cancer	We will select specific protein A from circulating exosomes of pancreatic cancer patients for further analysis.	Up to 2 years from start of study
The expression of protein A in the circulating exosomes from patients	By detecting the expression of protein A in circulating exosomes of patients. the ROC curve of A+ circulating exosomes will be compared to clinical standard tumor biomarkers (e.g., CA199) in pancreatic cancer patients.	Up to 2 years from start of study

Secondary Outcome Measures	Measure Description	Time Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:
1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

Patients

Caregivers

Clinical Trial Record